Ghassan Abou-Alfa: MSK Cancer Center keeps pressing for new therapy for fibrolamellar carcinoma

Ghassan Abou-Alfa, Associate Attending at Memorial Sloan Kettering Cancer Center, shared on X:

“Memorial Sloan Kettering Cancer Center, MSK Department of Medicine keep pressing for new therapy for fibrolamellar carcinoma.

Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without mTOR Inhibitors in Patients with Fibrolamellar Carcinoma.”

Additional information.
Source: Ghassan Abou-Alfa/X